Imperial College London
Portrait Picture

DrRuiPinto

Faculty of Medicine, School of Public Health

Research Associate in Chemometrics/Metabolomics
 
 
 
//

Contact

 

+44 (0)20 7594 9761r.pinto Website

 
 
//

Location

 

155Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Stenson:2016:10.3109/10428194.2016.1140164,
author = {Stenson, M and Pedersen, A and Hasselblom, S and Nilsson-Ehle, H and Karlsson, BG and Pinto, R and Andersson, P-O},
doi = {10.3109/10428194.2016.1140164},
journal = {Leuk Lymphoma},
pages = {1814--1822},
title = {Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients - a pilot study.},
url = {http://dx.doi.org/10.3109/10428194.2016.1140164},
volume = {57},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The prognosis for diffuse large B-cell lymphoma (DLBCL) patients with early relapse or refractory disease is dismal. To determine if clinical outcome correlated to diverse serum metabolomic profiles, we used (1)H nuclear magnetic resonance (NMR) spectroscopy and compared two groups of DLBCL patients treated with immunochemotherapy: i) refractory/early relapse (REF/REL; n=27) and ii) long-term progression-free (CURED; n = 60). A supervised multivariate analysis showed a separation between the groups. Among discriminating metabolites higher in the REF/REL group were the amino acids lysine and arginine, the degradation product cadaverine and a compound in oxidative stress (2-hydroxybutyrate). In contrast, the amino acids aspartate, valine and ornithine, and a metabolite in the glutathione cycle, pyroglutamate, were higher in CURED patients. Together, our data indicate that NMR-based serum metabolomics can identify a signature for DLBCL patients with high-risk of failing immunochemotherapy, prompting for larger validating studies which could lead to more individualized treatment of this disease.
AU  - Stenson,M
AU  - Pedersen,A
AU  - Hasselblom,S
AU  - Nilsson-Ehle,H
AU  - Karlsson,BG
AU  - Pinto,R
AU  - Andersson,P-O
DO  - 10.3109/10428194.2016.1140164
EP  - 1822
PY  - 2016///
SP  - 1814
TI  - Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients - a pilot study.
T2  - Leuk Lymphoma
UR  - http://dx.doi.org/10.3109/10428194.2016.1140164
UR  - https://www.ncbi.nlm.nih.gov/pubmed/26887805
VL  - 57
ER  -
Download